Artal Group S.A. held its position in REGENXBIO Inc. (NASDAQ:RGNX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 160,000 shares of the biotechnology company’s stock at the end of the 2nd quarter. Artal Group S.A. owned approximately 0.52% of REGENXBIO worth $3,160,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the stock. Redmile Group LLC purchased a new stake in REGENXBIO during the first quarter worth $24,494,000. Victory Capital Management Inc. lifted its position in shares of REGENXBIO by 30.9% in the first quarter. Victory Capital Management Inc. now owns 46,969 shares of the biotechnology company’s stock valued at $907,000 after acquiring an additional 11,079 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of REGENXBIO by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock valued at $1,423,000 after acquiring an additional 4,275 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of REGENXBIO in the first quarter valued at $272,000. Finally, Vanguard Group Inc. lifted its position in shares of REGENXBIO by 23.2% in the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after acquiring an additional 184,700 shares in the last quarter. Hedge funds and other institutional investors own 73.23% of the company’s stock.
Several brokerages have recently issued reports on RGNX. Chardan Capital restated a “buy” rating and issued a $75.00 price objective (up from $55.00) on shares of REGENXBIO in a research report on Tuesday, September 5th. Zacks Investment Research lowered REGENXBIO from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Evercore ISI started coverage on REGENXBIO in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Finally, BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. REGENXBIO currently has an average rating of “Buy” and a consensus target price of $37.00.
Shares of REGENXBIO Inc. (NASDAQ:RGNX) traded down 3.607% during midday trading on Tuesday, reaching $28.725. The company’s stock had a trading volume of 198,659 shares. REGENXBIO Inc. has a 52 week low of $13.61 and a 52 week high of $30.25. The stock’s market capitalization is $887.43 million. The stock has a 50-day moving average price of $27.11 and a 200 day moving average price of $26.04.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The business had revenue of $6.56 million during the quarter. Equities analysts forecast that REGENXBIO Inc. will post ($2.87) earnings per share for the current year.
In related news, Director Donald J. Hayden, Jr. sold 20,000 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $24.95, for a total transaction of $499,000.00. Following the completion of the sale, the director now directly owns 20,000 shares in the company, valued at $499,000. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Vittal Vasista sold 3,040 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $21.09, for a total value of $64,113.60. Following the sale, the chief financial officer now owns 103,118 shares of the company’s stock, valued at $2,174,758.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,640 shares of company stock valued at $2,638,640. 17.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/19/artal-group-s-a-maintains-stake-in-regenxbio-inc-rgnx.html.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.